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Memory CD4+ T helper (Th) cells provide long-term
protection against pathogens and are essential for
the development of vaccines; however, some anti-
gen-specific memory Th cells also drive immune-
related pathology, including asthma. The mecha-
nisms regulating the pathogenicity of memory Th
cells remain poorly understood. We found that inter-
leukin-33 (IL-33)-ST2 signals selectively licensed
memory Th2 cells to induce allergic airway inflamma-
tion via production of IL-5 and that the p38 MAP ki-
nase pathway was a central downstream target of
IL-33-ST2 in memory Th2 cells. In addition, we found
that IL-33 induced upregulation of IL-5 by memory
CD4+ T cells isolated from nasal polyps of patients
with eosinophilic chronic rhinosinusitis. Thus, IL-33-
ST2-p38 signaling appears to directly instruct patho-
genic memory Th2 cells to produce IL-5 and induce
eosinophilic inflammation.
INTRODUCTION
The quality of adaptive immune responses depends on the
number and function of antigen-specific memory T cells.
Upon antigen recognition via the T cell receptor (TCR), naive
CD4+ T cells undergo rapid clonal expansion, followed by differ-
entiation into functionally distinct T helper (Th) cell subsets, such
as Th1, Th2, and Th17 cells (O’Shea and Paul, 2010; Reiner,
2007). Some of these effector Th cells are maintained as mem-
ory Th cells for long times in vivo (Nakayama and Yamashita,
2008), and it is now becoming clear that these cells display
functional heterogeneity (Sallusto and Lanzavecchia, 2009).
Recent reports indicate that there are several distinct sub-
sets of memory type Th2 cells that produce large amounts of294 Immunity 42, 294–308, February 17, 2015 ª2015 Elsevier Inc.interleukin-5 (IL-5), IL-17, or interferon-g (IFN-g) in addition to
IL-4 and IL-13 (Endo et al., 2014; Endo et al., 2011; Hegazy
et al., 2010; Islam et al., 2011; Upadhyaya et al., 2011; Wang
et al., 2010). In particular, IL-5-producing memory Th2 cell sub-
sets appear to be crucial drivers of the pathology of allergic dis-
eases in the airway and skin (Endo et al., 2011; Islam et al.,
2011). However, environmental cues and signals that dictate
how memory Th2 cells contribute to the pathogenicity of allergic
diseases, including chronic airway inflammation, are poorly
understood.
Asthma is a chronic lower-airway inflammatory disease char-
acterized by recurrent airway obstruction and wheezing (Cohn
et al., 2004). Allergic asthma ismainly driven by Th2-cell-type cy-
tokines, such as IL-4, IL-5, and IL-13, and is characterized by the
presence of elevated numbers of eosinophils in the lungs (Cohn
et al., 2004). IL-5 regulates eosinophil development, recruitment
to the lungs, and activation (Rosenberg et al., 2013). IL-13 plays
an important role in the effector phase of asthma by inducing
airway remodeling and airway hyperresponsiveness (AHR) as
well as mucus hyperproduction (Ingram and Kraft, 2012). Th2
cells are the major source of IL-4, IL-5, and IL-13 in allergic
asthma. Innate Th2 cell counterparts that also produce large
amounts of IL-5 and IL-13 (LinCD127+ type 2 innate lymphoid
cells [ILC2s]) have been identified (Furusawa et al., 2013; Lloyd,
2010; Price et al., 2010; Saenz et al., 2010). Recent research
indicates that ILC2s play a critical role in eosinophilic airway
inflammation in mice that lack the ability to mount adaptive im-
mune responses (Chang et al., 2011; Halim et al., 2012; Scanlon
and McKenzie, 2012).
Chronic rhinosinusitis (CRS) is a common chronic sinus inflam-
matory disease characterized by distinct cytokine production
profiles and tissue-remodeling patterns (Hamilos, 2011; Van
Bruaene et al., 2008; Zhang et al., 2008). CRS can be classified
into two types of diseases according to the presence of nasal
polyps. CRS with nasal polyps (CRSwNP) is often accompanied
by Th2-cell-skewed eosinophilic inflammation, whereas CRS
without nasal polyps (CRSsNP) is characterized by a predomi-
nantly Th1-cell-skewed response (Hamilos, 2011). IL-5 is more
abundant in the nasal mucosal tissues of CRSwNP than in those
of CRSsNP (Van Bruaene et al., 2008). CRSwNP is further subdi-
vided into two types of diseases on the basis of the extent of
eosinophilic inflammation, particularly for people in East Asia
(Zhang et al., 2008): eosinophilic CRS (ECRS) and non-eosino-
philic rhinosinusitis (NECRS).
IL-33, a member of the IL-1 family, was newly identified as the
ligand for the ST2 receptor (also known as IL-1RL1) (Liew et al.,
2010; Schmitz et al., 2005). The major genome-wide association
studies have reproducibly found significant associations be-
tween IL33 and IL1RL1 genetic variants and asthma in humans
(Bønnelykke et al., 2014; Grotenboer et al., 2013; Torgerson
et al., 2011). IL-33 expression is higher in asthmatic patients
and in mouse models of asthma (Lloyd, 2010). Epithelial and
airway smooth muscle cells appear to represent two major sour-
ces of IL-33 in asthmatics (Pre´fontaine et al., 2009). Previous
reports showed that the depletion of IL-33 or ST2 attenuatedmu-
rine ovalbumin (OVA)-induced airway inflammation (Kurowska-
Stolarska et al., 2008; Oboki et al., 2010). ILC2s are character-
ized by their rapid production of IL-5 and IL-13 in response to
IL-33 exposure (Scanlon and McKenzie, 2012). Therefore, un-
derstanding the mechanisms by which IL-33 induces allergic
inflammation and differentiating between antigen-specific and
antigen-independent functions of IL-33 are crucial for the effec-
tive design of therapeutics for patients with allergic inflammatory
disorders such as chronic asthma.
We herein investigated the role of IL-33 in allergic airway
inflammation induced by memory Th2 cells. We found that IL-
33-ST2 signaling was crucial for the induction of pathogenicity
of memory Th2 cells in allergic experimental asthma. Moreover,
we found that like ILC2s, memory Th2 cells acquired the ability to
produce IL-5 directly in response to IL-33; this property was not
observed in effector Th2 cells. Genetic deletion of IL-33 or ST2
resulted in impaired memory-Th2-cell-dependent eosinophilic
airway inflammation, and we identified p38 mitogen-activated
protein kinase (MAPK) as the downstream target of IL-33-ST2
signaling in this cell type. Analysis of nasal polyps from patients
with CRS showed that IL-33 could also directly enhance IL-5
production by human memory CD4+ T cells. Thus, we propose
that the IL-33-ST2-p38 axis is crucial for the induction of patho-
genicity of memory Th2 cells in eosinophilic airway inflammation
in both mice and humans.
RESULTS
IL-33 Selectively Enhances IL-5 Production by Memory
Th2 Cells
IL-33 is known to induce strong Th2-cell-type immune re-
sponses and eosinophilic inflammation in the lung and intestine
(Lloyd, 2010). However, the types of cells on which IL-33 acts in
these settings are still being defined. To explore the involvement
of CD4+ T cells in IL-33-mediated inflammation, we assessed
the expression of the IL-33 receptor (ST2) on naive CD4+
T cells, effector Th1 and Th2 cells generated in vitro, and mem-
ory Th1 and Th2 cells generated in vivo (Nakayama and Yama-
shita, 2008) (Figure S1A). Memory Th2 cells showed very high
expression of IL-7 receptor-a chain (IL-7Ra), and the majority
also showed low expression of CD69 and IL-2Ra (Figure S1B,
upper panel). Expression patterns of these surface receptorswere quite different from that seen on the in-vitro-generated
effector Th2 cells used in this study. We observed that
compared to naive CD4+ T cells or memory Th1 cells, memory
Th2 cells showed strongly increased expression of Il1rl1 mRNA
(Figure 1A). Compared to naive CD4+ T cells or effector Th1
cells, effector Th2 cells also showed significantly higher expres-
sion of Il1rl1 (p < 0.01; Mann-Whitney U test), but this was not as
pronounced as the expression observed in memory Th2 cells.
The increased Il1rl1 mRNA was also reflected by higher expres-
sion of ST2 on the surface of memory Th2 cells than on the
surface of naive CD4+ T cells or effector Th2 cells (Figure 1B).
Substantial ST2 expression was detected only on memory
Th2 cells, and ST2 was specifically found on those cells with
high expression of IL-7Ra and low expression of CD69 and
IL-2Ra, strongly indicating that a distinct subset of ST2-ex-
pressing cells is induced in memory Th2 cells (Figure S1B, lower
panel). In addition, exposure of memory Th2 cells to IL-33
dramatically enhanced ST2 expression (Figure 1C). Importantly,
we found that stimulation with IL-33 for 5 days selectively
induced IL-5 production by memory Th2 cells but not by
effector Th2 cells (Figure 1D). In contrast, IL-33-induced upre-
gulation of IL-4 expression was not observed in response to
treatment with IL-33 (Figures 1D and 1F). IL-13 was slightly
increased by cultivation of memory Th2 cells with IL-33 (Figures
1E and 1F). IL-33 supported the viability of memory Th2 cells as
well as IL-2 and IL-7 (Figure S1C) without inducing significant
proliferation (Figure S1D). We reported previously that memory
Th2 cells can be subdivided into four distinct subpopulations
according to the expression of CXCR3 and CD62L and that
IL-5 production is normally restricted to a small number of cells
in the CD62LloCXCR3lo subpopulation (Endo et al., 2011) (Fig-
ure S1E). We also examined the effect of IL-33 on the four
subpopulations (CXCR3 and CD62L) of memory Th2 cells.
ST2 expression was detected on 10%–20% of all four sub-
populations of freshly prepared memory Th2 cells (Figure S1F,
left). IL-33 treatment enhanced ST2 expression on all four
subpopulations (Figure S1F, right). Upon TCR stimulation, IL-
5-producing cells were detected only in the CD62LloCXCR3lo
subpopulation of freshly prepared memory Th2 cells (Fig-
ure S1G, left), whereas after IL-33 cultivation, IL-5-producing
cells were detected in all four subpopulations and showed their
highest numbers in the CD62LloCXCR3lo subpopulation (Fig-
ure S1G, right). IL-5 production was also assessed by ELISA,
and similar results were obtained (Figure S1H). Thus, these re-
sults indicate that IL-33 upregulates ST2 expression and selec-
tively enhances IL-5 expression and production by memory Th2
cells, but not effector Th2 cells.
IL-33 Induces Selective Remodeling of Chromatin at the
Il5 Locus in Memory Th2 Cells
Epigenetic chromatin modifications can control selective ex-
pression of genes that function in the immune system (Northrup
and Zhao, 2011). We therefore explored whether IL-33 signaling
could regulate the chromatin status of the Th2-cell-associated
cytokine-encoding genetic loci in memory Th2 cells. We per-
formed chromatin immunoprecipitation (ChIP) assays with
antibodies specific to several histone modifications (Figure 2A).
At the Il5 locus, freshly prepared in-vivo-generated memory
Th2 cells showed lower modifications associated with activeImmunity 42, 294–308, February 17, 2015 ª2015 Elsevier Inc. 295
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Figure 1. IL-33 Selectively Induces IL-5 Production by Memory Th2 Cells
(A) Quantitative RT-PCR analysis of Il1rl1 in the indicated cell types. Relative expression (normalized to Hprt) is shown with SDs.
(B) Expression profiles of ST2 on the indicated cell types.
(C) Expression profiles of ST2 on memory Th2 cells before (blue) and after (red) culture with IL-33.
(D) Memory and effector Th2 cells were cultured with IL-33 for 5 days. The cultured cells were stimulated with immobilized anti-TCRb for 6 hr. Intracellular-staining
profiles of IL-5 and IL-4 are shown.
(E) Intracellular-staining profiles of IL-13 in effector and memory Th2 cells before and after culture with IL-33 are shown.
(F) Quantitative RT-PCR analysis of the indicated genes in memory Th2 cells before and after culture with IL-33.
More than five independent experiments were performed and showed similar results (**p < 0.01; NS, not significant; Mann-Whitney U test; A–F). Three technical
replicates were performed with quantitative RT-PCR (A and F). See also Figure S1.transcription (H3-K4 trimethylation and H3-K9 acetylation) and
higher modifications associated with genetic repression (H3-
K27 trimethylation) than did effector Th2 cells (Figure 2B), indi-
cating that these modifications were not efficiently maintained
during the transition to the memory phase. However, after
stimulation of memory Th2 cells with IL-33 (without TCR stimula-
tion), H3-K4 trimethylation and H3-K9 acetylation increased
and H3-K27 trimethylation decreased at the Il5 locus, indicating
that IL-33 could restore the chromatin-modification signature
observed in IL-5-producing effector Th2 cells. In contrast to his-
tone modifications at the Il5 locus, those at the other Th2 cell
cytokine-encoding loci (Il4p, Il13p, and Va enhancer) were not
obviously affected by IL-33 stimulation (Figures S2A and S2B).
We also observed increased H3-K4 trimethylation and H3-K9
acetylation at the Il1rl1 locus in IL-33-stimulated memory Th2
cells (Figures S2C and S2D). These changes in histone modifica-
tions at the Il5 locus were specific to IL-33 because no obvious
change was detected in memory Th2 cells treated with IL-2,
IL-7, or IL-25 (Figure S2E). It has previously been shown that296 Immunity 42, 294–308, February 17, 2015 ª2015 Elsevier Inc.like IL-33, a combination of IL-2 and IL-25 can induce IL-5 pro-
duction in ILC2s (Furusawa et al., 2013). We examined the syn-
ergistic effect of IL-2 and IL-25 on IL-5 production by memory
Th2 cells, and indeed cultivation with IL-2 and IL-25, similar to
IL-33 cultivation, increased IL-5 production in memory Th2 cells
(Figure S2F). Next, we performedChIP assays to assess whether
the chromatin remodeling at the Il5 locus of memory Th2 cells
was induced by the combination of IL-2 and IL-25. Active histone
modifications were increased and repressive histone modifica-
tions were decreased at the Il5 locus in memory Th2 cells after
culture with both IL-2 and IL-25 (Figure S2G). The IL-33-induced
histone modifications at the Il5 locus were accompanied by
enhanced recruitment of p300, a component of the histone
acetyl transferase (HAT) complex, and RNA polymerase ll (pol
II) (Figure 2C). Stronger binding of pol II to the Il5 locus, including
the transcribed region in IL-33-cultured memory Th2 cells, was
detected. These results indicate that IL-33, as well as the combi-
nation of IL-2 and IL-25, remodels chromatin structure to be
permissive for transcription at the Il5 locus in memory Th2 cells.
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Figure 2. IL-33 Selectively Remodels Chromatin Structure at the Il5 Locus in Memory Th2 Cells Independently of TCR Stimulation
(A) Schematic representation of the mouse Il5 locus. The locations of primers and probes (upstream region 2 [U2] to Il5 intron 1 [int.1]) and exons are indicated.
(B) ChIP assays were performed with anti-trimethyl histone H3-K4, anti-acetyl histone H3K9, and anti-trimethyl histone H3K27 at the Il5 locus from effector Th1,
effector Th2, freshly prepared memory Th2, and memory Th2 cells cultured with IL-33 for 5 days. The relative intensities (relative to input DNA) of these mod-
ifications were determined by quantitative RT-PCR analysis. More than three independent experiments were performed and showed similar results.
(C) The binding of p300 and pol II to the Il5 locus in the indicated cell types was detected by ChIP with quantitative RT-PCR analysis.
Two independent experiments were performed and showed similar results. Three technical replicates were performed with quantitative RT-PCR (B and C). See
also Figure S2.Because TCR stimulation was not included in this culture sys-
tem, it appears as though the observed chromatin remodeling
was solely induced by cytokine signaling.
The IL-33-ST2 Pathway Enhances IL-5 Production by
Memory Th2 Cells In Vivo
We used Il1rl1-deficient (Il1rl1/) mice in order to directly
demonstrate the involvement of the IL-33-ST2 pathway in the
generation of IL-5-producing memory Th2 cells. In the absence
of ST2, effector Th2 cell differentiation was not impaired, and
memory Th2 cells were generated normally in vivo (Figures
S3A and S3B). As expected, IL-33-induced IL-5 augmentation
was not observed in Il1rl1/ memory Th2 cells (Figure 3A).
Next, we assessed the effect of IL-33 on the IL-5 production of
memory Th2 cells in vivo, as illustrated in Figure 3B. Administra-
tion of IL-33 increased ST2 expression (Figure 3C) and IL-5
production (Figure 3D) of Il1rl1+/+ memory Th2 cells but did not
substantially alter expression of ST2 or IL-5 production by
Il1rl1/ memory Th2 cells. These results indicate that memory
Th2 cells respond to IL-33 in vivo by increasing ST2 expression
and producing IL-5, as was observed in memory Th2 cells after
cultivation with IL-33 in vitro.We also generated non-transgenic memory CD4+ T cells by
using an OVA-alum (OVA with aluminum) immunization system
in vivo, as depicted in Figure 3E. A substantial proportion of
non-TCR transgenic memory CD4+ T cells expressed ST2 (Fig-
ure 3F and Figure S3C), and IL-33-induced IL-5 augmentation
was detected in Il1rl1+/+ memory CD4+ T cells, but not in Il1rl1/
memory CD4+ T cells (Figure 3G). Thus, the IL-33-ST2 pathway
is critical for the induction of ST2 expression and generation of
IL-5-producing memory Th2 cells in vivo.
Memory-Th2-Cell-Dependent Eosinophilic Airway
Inflammation and AHR Are Ameliorated by the Depletion
of IL-33 or ST2
In order to assess the role of the IL-33-ST2 pathway in the path-
ological function of memory Th2 cells, we used memory-Th2-
cell-dependent airway-inflammation models, as illustrated in
Figure 4A. The expression of Il33 in the lung was increased after
OVA challenge by inhalation, whereas the expression of Il33 in
the spleen was not increased even after OVA challenge (Fig-
ure 4B). In this model, ST2-expressing cells were increased after
OVA challenge in the lung, and highly ST2-expressing cells were
found in the CXCR3 memory Th2 cell population (indicated byImmunity 42, 294–308, February 17, 2015 ª2015 Elsevier Inc. 297
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Figure 3. The IL-33-ST2 Pathway Enhances
IL-5 Production by Memory Th2 Cells In Vivo
(A) Intracellular-staining profiles of IL-5 and IL-4 in
Il1rl1+/+ or Il1rl1/ memory Th2 cells before (left,
control) and after (right, IL-33) cultivation with IL-
33. Five independent experiments were performed
and showed similar results.
(B) Experimental protocols for the injection of IL-33
into the mice that received Il1rl1+/+ or Il1rl1/
memory Th2 cells.
(C) ST2 and CXCR3 expression profiles of KJ1+
memory Th2 cells recovered from the lungs of
mice that received Il1rl1+/+ (left) or Il1rl1/ (right)
memory Th2 cells.
(D) KJ1+ memory Th2 cells shown in (C) were
stimulated in vitro with immobilized anti-TCRb for
6 hr. Intracellular-staining profiles of IL-5 and IL-4
are shown.
(E) Experimental protocols for the generation of
non-TCR transgenic memory CD4+ T cells in vivo.
(F) Cell-surface-expression profiles of ST2 and
CXCR3 on Il1rl1+/+ or Il1rl1/CD44+ memory type
CD4+ T cells are shown.
(G) Il1rl1+/+ or Il1rl1/memory CD4+ T cells shown
in (F) were stimulated with OVA-pulsed antigen-
presenting cells for 24 hr before (upper) and after
(lower) cultivation with IL-33. Intracellular-staining
profiles of IL-5 and CD44 are shown with the per-
centage of cells in each area.
Two independent experiments were performed
and showed similar results, and five technical
replicates were included (C, D, F, and G). See also
Figure S3.
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an arrow, Figure 4C, middle). Only a small number of ST2-ex-
pressing cells were detected in endogenous lung CD4+ T cells
even after OVA challenge (Figure 4C, right).
Next, OVA-specific Il1rl1+/+ or Il1rl1/memory Th2 cells were
transferred into wild-type BALB/c recipients, and their ability to
induce airway inflammation was assessed. Compared to the
Il1rl1+/+ group, the Il1rl1/ group showed a significant decrease
(p < 0.01; Mann-Whitney U test) in the number of inflammatory
eosinophils in the bronchoalveolar lavage (BAL) fluid (Figures
4D and S4A). No obvious changes in numbers of infiltrated cells
were detected in OVA-challenged Il1rl1+/+ and Il1rl1/ mice
that had not received memory Th2 cells. Histological analysis
also revealed a similar reduction in mononuclear cell infiltration
into the peribronchiolar regions of the lungs (Figure 4E). Periodic
acid-Schiff (PAS) staining showed decreased production of
mucus in the Il1rl1/ group (Figure 4F). Conversely, similar
eosinophilic infiltration into the BAL fluid was observed from the
mice that received Il1rl1+/+ and Il1rl1/ effector Th2 cells that
were challenged with OVA on days 1 and 3 (Figures S4B and
S4C). These results support the observation that effector Th2
cells possess little reactivity to IL-33 and that this pathway is
less important for induction of eosinophilic inflammation by
effector Th2 cells than for induction by memory Th2 cells. We
also performed a set of in vivo kinetics experiments to better
define the timing of acquisition of IL-33 responsiveness bymem-
ory Th2 cells. Eosinophilic airway inflammation, IL-5-producing
Th2 cells in the lung, and IL-5 in the BAL fluid were assessed 6
or 35 days after the transfer of Il1rl1+/+ and Il1rl1/ effector Th2
cells (FiguresS4D–S4K). Six days after cell transfer, no significant
difference was detected in these three parameters between
the Il1rl1/ and Il1rl1+/+ groups (Figures S4D–S4G). In contrast,
significant decreases in eosinophilic infiltration (p < 0.01; Mann-
Whitney U test), generation of IL-5-producing Th2 cells, and IL-
5 productionwere observed in theday-35 Il1rl1/group (Figures
S4H–S4K). We also examined the OVA-induced airway inflam-
mation in OVA-immunized Il1rl1+/+ and Il1rl1/mice at different
time points (12 or 45 days after OVA immunization) (Figures S4L–
S4S). Significantly decreased infiltration of eosinophils into the
BAL fluid (p < 0.01; Mann-Whitney U test), reduced IL-5-produc-
ing Th2 cells in the lung, and decreased IL-5 production in the
BAL fluid were observed in the Il1rl1/ group 45 days after, but
not 12 days after, the last immunization. These results indicate
that ST2-mediated induction of IL-5 and exacerbation of eosino-
philic airway inflammation were acquired by memory Th2 cells
35 days after effector Th2 cell transfer or 45 days after antigenic
immunization, but not at the earlier time points analyzed.Figure 4. The Pathogenicity of Memory Th2 Cells Is Ameliorated by Lo
(A) Experimental protocols for memory-Th2-cell-dependent allergic inflammation
(B–I) Mice were treated as described in (A). (B) Quantitative RT-PCR analysis of Il
memory Th2 cells frommicewith no challenge (left) or OVA challenge (center) and e
cell numbers of eosinophils (Eos), neutrophils (Neu), lymphocytes (Lym), andmacr
shown with SDs. (E and F) Lungs were fixed and stained with H&E or PAS. A repre
the indicated cytokines in the BAL fluid from the experimental groups shown in
Il1rl1/ memory Th2 cells in the lung. (I) Lung resistance (RL) was assessed in r
group) are shown with SDs.
(J) The absolute cell numbers of leukocytes in the BAL fluid. Mean values (five m
(K) ELISA analysis of the indicated cytokines in the BAL fluid from the experimen
Three (B–H) or two (J and K) independent experiments were performed and showe
in quantitative RT-PCR analysis (B). Five technical replicates were included in EL
300 Immunity 42, 294–308, February 17, 2015 ª2015 Elsevier Inc.The amount of IL-5 in the BAL fluid was significantly lower (p <
0.01; Mann-Whitney U test) in the Il1rl1/ memory Th2 cell
group than in the Il1rl1+/+ group, whereas the amount of IL-4
was almost equivalent between the two groups (Figure 4G).
We also detected a modest but significant reduction in IL-13
(p < 0.05; Mann-Whitney U test). Consistent with these observa-
tions, fewer IL-5-producing memory Th2 cells were detected in
the lungs of mice from the Il1rl1/ group than in those from
the Il1rl1+/+ group after OVA inhalation (Figure 4H, left), whereas
decreases in IL-4- and IL-13-producing cells were less promi-
nent. Th2-cell-associated cytokine production was not substan-
tially different between endogenous Il1rl1+/+ and Il1rl1/ CD4+
T cells (Figure 4H, right). In addition, comparable proportions
of Th2-cell-associated cytokine-producing memory Th2 cells
were observed in the spleens of mice from the Il1rl1/ and
Il1rl1+/+ groups (Figure S4T). These data are consistent with
the absence of change in Il33 expression in the spleen after
OVA challenge (Figure 4B). We also analyzed the degree of
AHR in the allergy-induced mice, which received Il1rl1+/+ or
Il1rl1/memory Th2 cells, by measuring methacholine-induced
airflow obstruction with a mechanical ventilator. The degree of
AHR in mice that received Il1rl1/ memory Th2 cells was lower
than that of mice that received Il1rl1+/+ memory Th2 cells (p <
0.05; Mann-Whitney U test) (Figure 4I).
Finally, we assessed the relative contribution of memory Th2
cells to eosinophilic inflammation given that it is already known
that ILC2s can respond to IL-33 by producing IL-5 in the lung
(Halim et al., 2012). We examined the effect of the depletion of
ILC2s on memory-Th2-cell-induced airway inflammation in the
lung by using CD90.2 antibody. In brief, CD90.1+ memory Th2
cells were transferred into CD90.2 Rag2/ mice, and CD90.2+
ILC2s were depleted by the administration of CD90.2 antibody
(Figures S4U and S4V). Thesemice were challenged with inhaled
OVA four times. The number of infiltrated eosinophils and the
concentration of IL-5 in the BAL fluid were found to be similar be-
tween control and ILC2-depleted groups (Figures 4J and 4K).
Therefore, at least in this system, the contribution of ILC2s to
eosinophilic inflammation is relatively minor.
Il33–/– Mice Have Impaired Generation of IL-5-Producing
Memory Th2 Cells and Reduced Eosinophilic Airway
Inflammation
We next assessed the function of IL-33 on memory Th2 cells by
using Il33+/+ and Il33/ mice as recipients with or without OVA
challenge (Figures S5A and S5B). First, we assessed the effect
of endogenous IL-33 on memory Th2 cells in the steady state.ss of IL-33-ST2 Signaling
.
33 in the spleen or lungs. (C) ST2 and CXCR3 expression profiles of lung KJ1+
ndogenous CD4+ T cells frommicewith OVA challenge (right). (D) The absolute
ophages (Mac) in the BAL fluid are shown.Mean values (fivemice per group) are
sentative staining pattern is shown. Scale bars represent 100 mm. (G) ELISA of
(D). (H) Intracellular-staining profiles of the indicated cytokines in Il1rl1+/+ or
esponse to increasing doses of methacholine. The mean values (five mice per
ice per group) are shown with SDs.
tal groups with memory Th2 cell transfer shown in (J).
d similar results (**p < 0.01; *p < 0.05). Three technical replicates were included
ISA on the BAL fluid samples (G and K). See also Figure S4.
A B
C D
E
F
G
*p < 0.05
**p < 0.01
**p < 0.01
Figure 5. Reduced Memory-Th2-Cell-Dependent Airway Inflammation in Il33–/– Mice
(A) ST2 and CXCR3 expression profiles of KJ1+ memory Th2 cells prepared from the spleens and lungs of Il33+/+ or Il33/ recipients.
(B) Quantitative RT-PCR analysis of Il1rl1 in lung memory Th2 cells from Il33+/+ or Il33/ recipients. Relative expression (normalized to Hprt) is shown with SDs.
(legend continued on next page)
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Compared to memory Th2 cells generated in Il33+/+ mice,
memory Th2 cells generated in Il33/mice (without OVA inhala-
tion) showed a moderate reduction of ST2 expression (Figures
5A and 5B) and significant reduction of IL-5-producing cells
(Figure 5C) (p < 0.05; Mann-Whitney U test). We also exam-
ined memory-Th2-cell-dependent airway inflammation by using
Il33+/+ and Il33/ mice as recipients (Figure S5B). The OVA-
induced highly ST2-expressing CXCR3 population was not de-
tected whenmemory Th2 cells were transferred into Il33/mice
(Figure 5D). Compared to the Il33+/+ group, mice from the Il33/
group displayed significantly decreased eosinophilic infiltration
(p < 0.01; Mann-Whitney U test; Figure 5E), and the amount of
IL-5 in the BAL fluid was significantly decreased (p < 0.01;
Mann-Whitney U test; Figure 5F). No obvious changes in the
numbers of infiltrated cells were detected in OVA-challenged
Il33+/+ and Il33/ mice that had not received memory Th2 cells
(Figure 5E). Consistent with these observations, fewer IL-5-pro-
ducingmemory Th2 cells were detected in the lungs ofmice from
the Il33/ group than in those of mice from the Il33+/+ group af-
ter OVA inhalation, whereas the percentages of IL-4- or IL-13-
producing cells were equivalent (Figure 5G, left). No substantial
changes in Th2-cell-associated cytokine production were de-
tected between Il33+/+ and Il33/ endogenous CD4+ T cells
(Figure 5G, right). Thus, endogenous IL-33 from the recipient
mice appears to be critical for the induction of memory-Th2-
cell-dependent eosinophilic airway inflammation.
p38 Is a Major Downstream Target of IL-33-Dependent
IL-5 Augmentation in Memory Th2 Cells
Next, we sought to identify which signaling pathway down-
stream of the ST2 receptor was responsible for the IL-33-depen-
dent augmentation of IL-5 production by memory Th2 cells.
Given that IL-33 has been reported to induce MAPK activation
and NF-kB phosphorylation in mast cells (Schmitz et al., 2005),
we first examined the effect of chemical inhibitors of several
components of these two pathways. We assessed the p38
MAPK inhibitor SB203580, the MEK inhibitor U0126, the JNK in-
hibitor SP600125, and the PI3K inhibitor Wortmannin. SB203580
inhibited the IL-33-induced IL-5 augmentation in memory Th2
cells, whereas the other inhibitors had little effect on IL-5 produc-
tion (Figure 6A). No change in IL-4 production was detected after
treatment with SB203580. We also used SB203580 to assess
whether the IL-2- and IL-25-induced IL-5 augmentation in mem-
ory Th2 cells was dependent on p38 MAPK pathway. As ex-
pected, SB203580 inhibited IL-2- and IL-25-induced IL-5
augmentation in memory Th2 cells (Figure S6). Phosphorylation
of p38 was induced by IL-33 and was inhibited by SB203580
(Figure 6B). A very small increase in p38 phosphorylation was
detected after culture with IL-2. Significant reductions in(C) Intracellular-staining profiles of IL-5 and KJ1.26 in lung memory Th2 cells and
(D) ST2 and CXCR3 expression profiles of lung KJ1+ memory Th2 cells in Il33+/+
(E) The absolute numbers of leukocytes in BAL fluid from Il33+/+ or Il33/mice tra
2 days after the last OVA challenge. The mean values (five mice per group) are s
(F) ELISA of the indicated cytokines in the BAL fluid from each experimental grou
(G) Intracellular-staining profiles of the indicated cytokines in lung memory Th2
challenging four times.
Two (A–C) or three (D–G) independent experiments were performed and showed s
with quantitative RT-PCR (B). Five technical replicates were performed with ELIS
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to SB203580 treatment of memory Th2 cells stimulated with
IL-33; however, no significant reduction was observed in Il4,
Il13, or Gata3 (p < 0.01; Mann-Whitney U test; Figure 6C). We
also detected marked reduction of ST2 after SB203580 treat-
ment of IL-33-stimulated memory Th2 cells (Figure 6D). We
next analyzed the effect of SB203580 on histone modifications
at the Il5 locus in memory Th2 cells. Memory Th2 cells cultured
with IL-33 in the presence of SB203580 showed reduced modi-
fications of H3-K4 methylation and H3-K9 acetylation at the Il5
locus, but not at the conserved GATA3 response element or
Va enhancer regions, which are located near the Il13 promoter
and downstream of the Il4 locus, respectively (Figure 6E). Spe-
cific reduction of Il5 and Il1rl1 expression in response to
siRNA-mediated silenced p38 in memory Th2 cells was also de-
tected, whereas silencing of p38 did not change IL-4 or IL-13
expression (Figure 6F). These results indicate that IL-33 selec-
tively activates p38, increases the expression of ST2, and aug-
ments the production of IL-5 in memory Th2 cells.
Human IL-33 Enhances IL-5 Production inMemory CD4+
T Cells from the Polyps of Patients with ECRS
Finally, we sought to gain more insight into the possible patho-
physiological effect of IL-33 on memory Th2 cells in human dis-
ease. We analyzed CD45RO+ memory CD4+ T cells from the
nasal polyps of patients with ECRS, which is characterized by
IL-5-dependent accumulation of large numbers of eosinophils
(Gevaert et al., 2006). We included samples from ECRS and
NECRS patients and categorized them by the number of eosin-
ophils found in the nasal polyps (Zhang et al., 2008). All patients
signed informed-consent forms, and the study was approved
by the ethics committee of the Chiba University Graduate
School of Medicine and each participating hospital (1006). The
number of IL-33+ endothelial cells in the nasal polyps was com-
parable between ECRS and NECRS patients (data not shown).
However, compared to nasal polyps from NECRS patients,
those from ECRS patients showed significantly elevated
numbers of IL-33+PECAM1+ endothelial cells (p < 0.05; Mann-
Whitney U test; Figure 7A). In addition, the baseline expression
of IL4 and IL5 (encoding Th2 cell cytokines), IL1RL1, and
GATA3 was higher in the ECRS polyps (Figure 7B). In contrast,
the expression of TBX21 was lower in the ECRS polyps. These
results prompted us to assess the effect of IL-33 on Th2 cell
cytokine production of memory CD4+ T cells from nasal polyps
of these patients. As a control, we analyzed the effect of IL-33
on cytokine expression by the CD45RO+CD4+ T cell population
of peripheral-bloodmononuclear cells (PBMCs) from healthy do-
nors. Very little expression of ST2 was detected on CD45RO+
CD4+ T cells from PBMCs, and no obvious augmentation inendogenous CD4+ T cells from Il33+/+ or Il33/ recipients.
or Il33/ recipients after OVA challenge.
nsferred with or without memory Th2 cells are shown. Samples were collected
hown with SDs.
p shown in (E).
cells and endogenous CD4+ T cells from Il33+/+ or Il33/ mice after OVA
imilar results (**p < 0.01; *p < 0.05). Three technical replicates were performed
A in BAL fluid (F). See also Figure S5.
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Figure 6. p38 Signaling Is Crucial for IL-33-Dependent IL-5 Induction by Memory Th2 Cells
(A) Intracellular-staining profiles of IL-5 and IL-4 in IL-33-treated memory Th2 cells with the indicated chemical inhibitors.
(B) The phosphorylated p38 (p-p38) and total p38 (p38) in freshly prepared memory Th2 cells stimulated with IL-2 or graded amounts of IL-33 with or without
SB203580.
(C) Quantitative RT-PCR analysis of the indicated genes in memory Th2 cells cultured with IL-33 with or without SB203580. Four independent experiments were
performed and showed similar results (**p < 0.01).
(D) Expression profiles of ST2 on memory Th2 cells treated with IL-33 with or without SB203580.
(legend continued on next page)
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IL-5 expression or productionwas detected after IL-33 treatment
(Figures S7A–S7C). However, IL-33 dramatically enhanced IL5
expression in CD45RO+CD4+ T cells from nasal polyps of
ECRS patients (p < 0.01; Mann-Whitney U test; Figure 7B).
Modest enhancement of IL13 expression was also detected
(p < 0.05; Mann-Whitney U test). In addition, the expression of
IL1RL1 was enhanced dramatically after IL-33 treatment, which
supported the results obtained from analysis of murine memory
Th2 cells (Figure 1). In contrast, no obvious effect of IL-33 on the
expression of IL5 or IL13 was detected in CD45RO+CD4+ T cells
from nasal polyps of NECRS patients. Furthermore, the expres-
sion and production of IL-5 and the IL1RL1 expression that was
enhanced by IL-33 in CD45RO+CD4+ T cells from nasal polyps
of ECRS patients were selectively inhibited by SB203580
treatment (p < 0.01; Mann-Whitney U test; Figures 7C and 7D).
These results indicate that IL-33 specifically induces enhanced
expression of IL1RL1 and IL-5 in CD45RO+CD4+ T cells from
nasal polyps of ECRS patients and that p38 activation is required
for IL-33-induced IL-5 augmentation. Thus, IL-33-ST2-p38
signaling might play an important role in the induction of patho-
genicity in tissue-infiltrating memory CD4+ T cells in human
chronic allergic inflammatory diseases such as ECRS.
DISCUSSION
Herein, we have identified memory Th2 cells as a critical target of
IL-33 in the pathogenesis of allergic airway inflammation in both
the murine and the human immune systems. IL-33 induced
increased expression of ST2 on memory Th2 cells and also
enhanced production of IL-5 both in vitro and in vivo. IL-33 expo-
sure induced chromatin remodeling at the Il5 locus. We found
that p38 MAPK was a downstream target of IL-33-ST2 signaling
in memory Th2 cells. In vivo, the depletion of IL-33 or ST2
attenuated memory-Th2-cell-mediated allergic responses in
the airway. Memory CD4+ T cells in the nasal polyps of ECRS pa-
tients showed increased IL-5 expression after stimulation with
IL-33, and IL-33 was highly expressed in the chronic inflamma-
tory polyps of ECRS patients. Thus, the IL-33-ST2-p38 pathway
could be a potential therapeutic target for treatment of chronic
allergic inflammation induced by memory Th2 cells.
IL-33-mediated production of IL-5 and IL-13 in ILC2s depends
on the phosphorylation of p38 (Furusawa et al., 2013), and IL-33
increases phosphorylation of p38 inmast cells (Liew et al., 2010).
In human T cells, IL-5 production induced by TCR stimulation is
dependent on p38 activity (Maneechotesuwan et al., 2007; Mori
et al., 1999). Likewise, we found that the p38-mediated signaling
pathway is critical for IL-33-induction of IL-5 expression in both
murine and human memory T cells. Thus, the p38 MAPK
pathway appears to be critical for the production of IL-5 in
various types of cells, including memory Th2 cells.
Chromatin remodeling of Il4 is dependent on the calcineurin-
NFAT pathway (Ansel et al., 2006), whereas that of IL-5 and
IL-13 appears to be more dependent on NF-kB, AP-1, or other(E) ChIP assays were performed as shown in Figure 2B. Histone modifications at
were measured by quantitative RT-PCR analysis.
(F) Effect of silenced p38 on Il5 expression in IL-33-culturedmemory Th2 cells. Me
5 days, and quantitative RT-PCR analysis of the indicated molecules after 4 hr s
At least three (A–D) or two (E and F) independent experiments were performed a
304 Immunity 42, 294–308, February 17, 2015 ª2015 Elsevier Inc.transcription factors rather than NFAT (Guo et al., 2009; Wang
et al., 2006). In the current study, we found that the p38 MAPK
pathway was activated by IL-33 and was responsible for the in-
duction of chromatin remodeling of the Il5 locus and thus left the
chromatin signature at the Il4 and Il13 loci almost unchanged.
Therefore, this might represent a connection between the IL-
33-p38 MAPK pathway and selective chromatin remodeling of
the Il5 locus.
An important finding from the present study is that IL-33-
induced chromatin remodeling at the Il5 locus in memory Th2
cells occurs independently from TCR stimulation. TCR stimula-
tion is indispensable for the induction of chromatin remodeling
at the Th1 and Th2 cell cytokine-encoding loci during differenti-
ation of naive CD4+ T cells into effector Th1 and Th2 cells (Na-
kayama and Yamashita, 2010). However, we have shown that
the cytokine IL-33 alone is capable of selectively inducing chro-
matin remodeling at the Il5 locus in memory Th2 cells. These re-
sults might indicate that IL-33 possesses a unique ability to
induce chromatin remodeling at the Il5 locus if the IL-33 receptor
ST2 is expressed. Indeed, IL-2, IL-7, or IL-25 did not induce
chromatin remodeling at the Il5 locus in memory Th2 cells,
although their receptors were expressed on memory Th2 cells.
The combination of IL-2 and IL-25 also induced chromatin
remodeling at the Il5 locus in memory Th2 cells, as shown previ-
ously in ILC2s (Halim et al., 2012), suggesting that similar mech-
anisms might operate cytokine-dependent IL-5 induction in
memory Th2 cells and ILC2s. In ILC2s, IL-33 is reported to be
more potent than IL-25 in inducing IL-13 production and AHR
(Barlow et al., 2013). At the Il5 locus, we detected permissive his-
tone marks accompanied by binding of p300 and pol II in mem-
ory Th2 cells stimulated with IL-33. Therefore, the activation of
the IL-33-ST2-p38 axis might induce the formation of a chro-
matin-remodeling complex, including the HAT complex, and re-
cruit it to the Il5 locus in memory Th2 cells.
We have demonstrated that memory Th2 cells are an impor-
tant target of IL-33 in the pathogenesis of airway inflammation.
We detected increased expression of Il33mRNA in the lung after
OVA challenge, which is consistent with the notion that tissue
damage leads to the release of IL-33 from structural cells, such
as epithelial cells and endothelial cells in the lung (Pre´fontaine
et al., 2009; Pre´fontaine et al., 2010), and that IL-33 is expressed
higher in asthmatic patients (Pre´fontaine et al., 2009). IL-33
secreted around the inflammatory airways might increase ST2
expression and IL-5 production by memory Th2 cells that are
either resident in or migrating through the lung tissue. Therefore,
IL-33 might enhance allergic airway responses through the in-
duction of our proposed IL-5-producing pathogenic memory
Th2 cells in the airway (Endo et al., 2014; Endo et al., 2011; He-
gazy et al., 2010; Islam et al., 2011; Upadhyaya et al., 2011;
Wang et al., 2010). Although it is already known that ILC2s
respond to IL-33 to produce IL-5 in the lung, the depletion of
ILC2s in Rag2/ mice by anti-CD90.2 antibody treatment did
not affect memory-Th2-cell-dependent airway inflammation.the Il5 locus in memory Th2 cells treated with IL-33 with or without SB203580
mory Th2 cells were introduced to control p38 siRNA and culturedwith IL-33 for
timulation with immobilized anti-TCRb is shown.
nd showed similar results. See also Figure S6.
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Figure 7. Human IL-33 Enhances IL-5 Production in Memory CD4+ T Cells Prepared from Nasal Polyps of ECRS Patients
(A) Immunofluorescent analysis (with staining for IL-33 [red], PECAM [green], and TOPRO3 [blue]) shows a representative section of nasal polyps from NECRS
(left) or ECRS (right) patients. The frequency of IL-33+PECAM1+ cells among PECAM+ cells of the nasal polyps from patients is shown (mean ± SD; n = 6 for ECRS
and n = 8 for NECRS).
(B) Quantitative RT-PCR analysis of relative expression of the indicated genes in human memory CD4+ T cells from nasal polyps (n = 11 for ECRS, n = 6 for
NECRS) was performed after 4 hr stimulation with PMA plus ionomycin. Relative expression (normalized to 18S) with SD is shown. Mean values and SDs are
shown.
(C) Human nasal memory CD4+ T cells were cultured with IL-33 with or without SB203580 for 5 days. Quantitative RT-PCR analysis of the indicated cytokines in
these cells after 4 hr stimulation with PMA plus ionomycin is shown.
(D) ELISA (n = 8 for ECRS and n = 5 for NECRS) of the indicated cytokines secreted by IL-33-cultured memory CD4+ T cells stimulated with PMA plus ionomycin
for 16 hr. The mean values of triplicate cultures with SDs are shown.
More than five independent experiments in each groupwere performed and showed similar results (**p < 0.01; *p < 0.05; C andD). Three technical replicateswere
performed with quantitative RT-PCR and ELISA (B–D). See also Figure S7.Thus, according to the experimental systems we used, IL-33 ap-
pears to act mainly on memory Th2 cells to increase their ability
to produce IL-5 and exacerbate eosinophilic inflammation. It re-
mains unknown whether IL-33 induces recruitment of memory
Th2 cells to the inflamed lung, given that IL-33 can also act as
a chemoattractant for Th2 cells (Komai-Koma et al., 2007).ECRS is a chronic inflammatory disease characterized by
prominent accumulation of eosinophils in the sinuses and nasal
polyp tissue (Gevaert et al., 2006). Functionally distinct popula-
tions of memory CD4+ T cells might be present within the nasal
polyps of ECRS and NECRS (Th1 cell type for NECRS and Th2
cell type for ECRS). We detected more IL-33-producing cells inImmunity 42, 294–308, February 17, 2015 ª2015 Elsevier Inc. 305
nasal polyps from ECRS patients than in those from NECRS
patients. Consistent with our findings in murine CD4+ T cells,
we demonstrated that IL-33 induced augmentation of IL5 and
IL1RL1 expression in memory CD4+ T cells from ECRS patients.
IL-33 induced expression of not only IL5 but also IL1RL1, sug-
gesting that a positive-feedbackmechanism resulted in a greater
responsiveness to IL-33 in memory CD4+ T cells from ECRS
patients. In addition, IL-33-induced IL-5 augmentation also de-
pended on the activation of p38. Our study clearly demonstrates
the function and pathophysiological role of IL-33 in ECRS, a
chronic inflammatory human disease.
In summary, our study has identified memory Th2 cells as an
important target of IL-33 in the pathogenesis of airway inflamma-
tion. The p38-mediated signaling pathway is critical for TCR-in-
dependent IL-33-induced IL-5 expression in both murine and
human memory Th2 cells. Further detailed studies focused on
the IL-33-ST2-p38-axis in pathogenic memory Th2 cells might
lead to the discovery of potential therapeutic targets for the treat-
ment of chronic allergic diseases.
EXPERIMENTAL PROCEDURES
Mice
The animals used in this study were backcrossed to BALB/c or C57BL/6 mice
ten times. Anti-OVA-specific TCR-ab (DO11.10) transgenic (Tg)micewere pro-
vided by Dr. D. Loh (Washington University School of Medicine, St. Louis)
(Murphy et al., 1990). Il33/ mice were generated as previously described
(Oboki et al., 2010). Il1rl1/ mice were kindly provided by Dr. Andrew N.J.
McKenzie (Medical Research Council, Cambridge) (Townsend et al., 2000).
Ly5.1 mice were purchased from Sankyo Laboratory. All mice were used at
6–8 weeks old and were maintained under specific-pathogen-free conditions.
BALB/c, BALB/c nu/nu, and Rag2/mice were purchased from CLEA Japan.
Animal care was conducted in accordance with the guidelines of Chiba
University.
The Generation and Culture of Effector and Memory Th2 Cells
Splenic CD62L+CD44KJ1+CD4+ T cells from DO11.10 OVA-specific TCR Tg
mice were stimulated with an OVA peptide (Loh15, 1 mM) plus antigen-pre-
senting cells (irradiated splenocytes) under Th2-cell-culture conditions
(25 U/ml IL-2, 10 U/ml IL-4, anti-IL-12 monoclonal antibody [mAb], and
anti-IFN-g mAb) for 6 days in vitro. The effector Th2 cells (3 3 106) were
transferred intravenously into BALB/c nu/nu or BALB/c recipient mice. Five
weeks after cell transfer, KJ1+CD4+ T cells in the spleen were purified by au-
toMACS (Miltenyi Biotec) and cell sorting (BD Aria II) and were then used as
memory Th2 cells.
Assessment of Memory Th2 Cell Function In Vivo
Memory Th2 cells were purified by fluorescence-activated cell sorting and
transferred (3 3 106/mouse) again into Il33+/+ or Il33/ mice. The mice were
exposed to aerosolized 1% OVA four times on days 1, 3, 9, and 11. For deple-
tion of ILC2s, Rag2/ mice were injected intraperitoneally with anti-CD90.2
(BioX Cell) antibody at a dose of 200 mg per day on days 2, 5, and 9. BAL fluid
for the analysis of cytokine production by ELISA was collected 12 hr after the
last challenge, and BAL fluid for the assessment of inflammatory cell infiltration
was collected on day 13. Intracellular-staining analysis was performed 12 hr
after the last inhalation. Lung histology was assessed on day 13. AHR was as-
sessed on day 12.
Quantitative Real-Time PCR
Total RNA was isolated with the TRIzol reagent (Invitrogen). cDNAwas synthe-
sized with an oligo (dT) primer and Superscript II RT (Invitrogen). Quantitative
real-time PCR was performed with the ABI PRISM 7500 Sequence Detection
System as described previously (Endo et al., 2011). Primers and TaqMan
probes were purchased from Applied Biosystems. Primers and Roche Univer-
sal probes were purchased from Sigma and Roche, respectively. Gene306 Immunity 42, 294–308, February 17, 2015 ª2015 Elsevier Inc.expression was normalized with the Hprt mRNA signal or the 18S ribosomal
RNA signal.
siRNA Analysis of Gene Targeting
siRNA was introduced into memory Th2 cells by electroporation with a mouse
T cell Nucleofector Kit and Nucleofector I (Amaxa). Memory Th2 cells were
transfected with 675 pmol of control random siRNA or siRNA for p38 (Applied
Biosystems) and cultured for 5 days with IL-33.
Nasal Polyp Mononuclear Cells and Homogenate Preparation
Nasal polyp mononuclear cells (NPMCs) were obtained as previously
described (Yamamoto et al., 2007). In brief, freshly obtained nasal polyps
were immediately minced and incubated in RPMI 1640 medium containing
1 mg/ml collagenase, 0.5 mg/ml hyaluronidase, and 0.2 mg/ml DNase I
(Sigma-Aldrich). After incubation, NPMCs were obtained by the Ficoll-Hypa-
que technique. A volume of 1 ml of PBS was added for every 100 mg of tissue
and was supplemented with aprotinin and leupeptin (Roche).
Statistical Analysis
Data were analyzed with GraphPad Prism software (version 6). Comparisons
of two groupswere calculatedwith non-parametricMann-Whitney U tests. Dif-
ferences with p values below 0.05 or 0.01 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
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